The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K

被引:373
作者
Gauthier, Jacques Yves [1 ]
Chauret, Nathalie [1 ]
Cromlish, Wanda [1 ]
Desmarais, Sylvie [1 ]
Duong, Le T. [2 ]
Falgueyret, Jean-Pierre [1 ]
Kimmel, Donald B. [2 ]
Lamontagne, Sonia [1 ]
Leger, Serge [1 ]
LeRiche, Tammy [1 ]
Li, Chun Sing [1 ]
Masse, Frederic [1 ]
Mckay, Daniel J. [1 ]
Nicoll-Griffith, Deborah A. [1 ]
Oballa, Renata A. [1 ]
Palmer, James T.
Percival, M. David [1 ]
Riendeau, Denis [1 ]
Robichaud, Joel [1 ]
Rodan, Gideon A. [2 ]
Rodan, Sevgi B. [2 ]
Seto, Carmai [1 ]
Therien, Michel [1 ]
Truong, Vouy-Linh [1 ]
Venuti, Michael C. [3 ]
Wesolowski, Gregg [2 ]
Young, Robert N. [1 ]
Zamboni, Robert [1 ]
Black, W. Cameron [1 ]
机构
[1] Merck Frosst Ctr Therapeut Res, Kirkland, PQ H9H 3L1, Canada
[2] Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA USA
[3] Celera Genomics Inc, San Francisco, CA 94080 USA
关键词
cathepsin K; cysteine protease; odanacatib; MK-0822; osteoporosis;
D O I
10.1016/j.bmcl.2007.12.047
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of the Cat K inhibitor L-873724. Substituting P1 and modifying the P2 side chain led to a metabolically robust inhibitor with a long half-life in preclinical species. Odanacatib was more selective in whole cell assays than the published Cat K inhibitors balicatib and relacatib. Evaluation in dermal fibroblast culture showed minimal intracellular collagen accumulation relative to less selective Cat K inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:923 / 928
页数:6
相关论文
共 23 条
[1]  
Adami S, 2006, J BONE MINER RES, V21, pS24
[2]  
ADAMI S, 2006, ASBMR 28 ANN M, P28
[3]   P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K [J].
Barrett, DG ;
Boncek, VM ;
Catalano, JG ;
Deaton, DN ;
Hassell, AM ;
Jurgensen, CH ;
Long, ST ;
McFadyen, RB ;
Miller, AB ;
Miller, LR ;
Payne, JA ;
Ray, JA ;
Samano, V ;
Shewchuk, LM ;
Tavares, FX ;
Wells-Knecht, KJ ;
Willard, DH ;
Wright, LL ;
Zhou, HQQ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (15) :3540-3546
[4]   Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K [J].
Black, WC ;
Bayly, CI ;
Davis, DE ;
Desmarais, S ;
Falgueyret, JP ;
Léger, S ;
Li, CS ;
Massé, F ;
McKay, DJ ;
Palmer, JT ;
Percival, MD ;
Robichaud, J ;
Tsou, N ;
Zamboni, R .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (21) :4741-4744
[5]   Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling [J].
Everts, V ;
VanderZee, E ;
Creemers, L ;
Beertsen, W .
HISTOCHEMICAL JOURNAL, 1996, 28 (04) :229-245
[6]  
FALAUEYRET, 2005, MED CHEM, V48, P7535
[7]   An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells [J].
Falgueyret, JP ;
Black, WC ;
Cromlish, W ;
Desmarais, S ;
Lamontagne, S ;
Mellon, C ;
Riendeau, D ;
Rodan, S ;
Tawa, P ;
Wesolowski, G ;
Bass, KE ;
Venkatraman, S ;
Percival, MD .
ANALYTICAL BIOCHEMISTRY, 2004, 335 (02) :218-227
[8]  
Grabowska UB, 2005, CURR OPIN DRUG DISC, V8, P619
[9]   Diastereoselective reductive Amination of aryl trifluoromethyl ketones and α-amino esters [J].
Hughes, Greg ;
Devine, Paul N. ;
Naber, John R. ;
O'Shea, Paul D. ;
Foster, Bruce S. ;
McKay, Daniel J. ;
Volante, R. P. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2007, 46 (11) :1839-1842
[10]   A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys [J].
Kumar, S. ;
Dare, L. ;
Vasko-Moser, J. A. ;
James, I. E. ;
Blake, S. M. ;
Rickard, D. J. ;
Hwang, S. -M. ;
Tomaszek, T. ;
Yamashita, D. S. ;
Marquis, R. W. ;
Oh, H. ;
Jeong, J. U. ;
Veber, D. F. ;
Gowen, M. ;
Lark, M. W. ;
Stroup, G. .
BONE, 2007, 40 (01) :122-131